Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $541M | $705M | $785M | $854M | $1.25B | $1.54B | $1.54B | $872M | $996M | $972M |
| Revenue growth | — | 30.2% | 11.3% | 8.9% | 46.2% | 23.6% | -0.1% | -43.5% | 14.2% | -2.4% |
| Operating income | $342M | $486M | — | — | — | — | — | — | — | — |
| Operating margin | 63.1% | 68.9% | — | — | — | — | — | — | — | — |
| Net income | $225M | $290M | $1.02B | $375M | $431M | $656M | $903M | -$556M | -$2.41B | -$277M |
| Net margin | 41.6% | 41.1% | 129.6% | 43.9% | 34.5% | 42.5% | 58.5% | -63.8% | -242.1% | -28.5% |
| EPS (diluted) | $0.86 | $0.82 | $2.76 | $0.87 | $0.81 | $1.11 | $1.50 | -$0.93 | -$4.02 | -$0.46 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $264M | $362M | $449M | $494M | $618M | $812M | $739M | $506M | $245M | $231M |
| Share buybacks | — | — | — | — | — | — | $17.9M | — | — | $23.4M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $83.2M | $171M | $821M | $1.46B | $550M | $459M | $236M | $250M | $332M | $541M |
| Total assets | $6.42B | $9.02B | $8.84B | $14.5B | $16.8B | $20.5B | $19.7B | $18.3B | $14.3B | $15.0B |
| Total liabilities | $3.17B | $5.19B | $4.28B | $7.44B | $9.49B | $12.1B | $11.1B | $10.7B | $9.46B | $10.4B |
| Long-term debt | $2.91B | $4.90B | $4.04B | $7.02B | $8.87B | $11.3B | $10.3B | $10.1B | $8.85B | $9.70B |
| Shareholders' equity | $3.25B | $3.82B | $4.55B | $7.03B | $7.34B | $8.44B | $8.59B | $7.63B | $4.83B | $4.61B |
| Retained earnings | -$434M | -$486M | $163M | $83.0M | -$71.4M | -$87.7M | $116M | -$972M | -$3.66B | -$4.14B |
| Shares (wtd avg diluted) | 261M | 350M | 366M | 428M | 530M | 590M | 599M | 599M | 600M | 601M |
Every figure is extracted from MEDICAL PROPERTIES TRUST INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.